Research programme: parathyroid hormone analogues - Xsira PharmaceuticalsAlternative Names: Non-desensitising parathyroid hormone analogues; Non-desensitising PTH analogues; Parathyroid hormone analogues - Xsira; PTH analogues - Xsira; PTH-NDL
Latest Information Update: 16 Jul 2016
At a glance
- Originator Xsira Pharmaceuticals
- Mechanism of Action G protein-coupled receptor agonists; Signal transduction pathway modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA
- 19 Jul 2006 Preclinical trials in Osteoporosis in USA (unspecified route)